1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Drugs In Development, 2022, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Anaphylaxis - Overview
- Anaphylaxis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anaphylaxis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anaphylaxis - Companies Involved in Therapeutics Development
- Allakos Inc
- Aquestive Therapeutics Inc
- ARS Pharmaceuticals Inc
- BioArdis LLC
- Bryn Pharma LLC
- Crossject SA
- Hoth Therapeutics Inc
- Klaria Pharma Holding AB
- Nasus Pharma Ltd
- Orexo AB
- Pharmacin BV
- PureIMS BV
- Anaphylaxis - Drug Profiles
- AK-006 - Drug Profile
- Product Description
- Mechanism Of Action
- AQST-109 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- HLK-0006 - Drug Profile
- Product Description
- Mechanism Of Action
- HT-KIT - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
- Product Description
- Mechanism Of Action
- MRGPRX2 Antagonist - Drug Profile
- Product Description
- Mechanism Of Action
- OX-640 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Anaphylaxis - Dormant Projects
- Anaphylaxis - Product Development Milestones
- Featured News & Press Releases
- Sep 13, 2022: Bryn Pharma announces completion of its pivotal study comparing UTULY epinephrine intranasal spray vs. 0.3 mg epinephrine autoinjector for the treatment of anaphylaxis
- Sep 01, 2022: First patent issued in Europe for Orexo’s adrenaline product OX640
- Jul 11, 2022: Aquestive Therapeutics reports positive results from final two arms of EPIPHAST Trial Supporting performance and real-world functionality of AQST-109 Epinephrine Oral Film
- Jul 05, 2022: Orexo's nasal adrenaline rescue medication OX640 enters clinical development
- Jun 15, 2022: Aquestive Therapeutics reports positive initial topline data from part 3 of EPIPHAST trial evaluating AQST-109 epinephrine oral Film
- Apr 12, 2022: Aquestive Therapeutics reports positive topline data from part 2 of EPIPHAST trial evaluating AQST-109 epinephrine oral film
- Mar 17, 2022: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-109 for emergency treatment of allergic reactions including anaphylaxis
- Feb 28, 2022: ARS Pharmaceuticals to share new data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting
- Feb 28, 2022: Aquestive Therapeutics presented positive topline Phase 1 results for AQST-109 epinephrine oral film at American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting
- Feb 25, 2022: Aquestive Therapeutics reports positive topline data from part 1 of EPIPHAST Trial evaluating AQST-109 epinephrine oral film
- Feb 24, 2022: Aquestive Therapeutics announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
- Feb 01, 2022: Phase 1 trial shows epinephrine can meet therapeutic thresholds when administered sublingually
- Dec 13, 2021: Aquestive Therapeutics receives written response to pre-IND submission for AQST-109 (epinephrine prodrug sublingual film) and begins recruitment for its epinephrine film pharmacokinetic and safety trial (EPIPHAST)
- Dec 02, 2021: Orexo develops a nasal adrenaline medication based on the novel amorphOX platform
- Nov 08, 2021: Hoth Therapeutics Inks API and drug product contracts with WuXi STA to advance manufacturing of HT-KIT cancer therapeutic
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Anaphylaxis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Anaphylaxis - Pipeline by Allakos Inc, 2022
- Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2022
- Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2022
- Anaphylaxis - Pipeline by BioArdis LLC, 2022
- Anaphylaxis - Pipeline by Bryn Pharma LLC, 2022
- Anaphylaxis - Pipeline by Crossject SA, 2022
- Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2022
- Anaphylaxis - Pipeline by Klaria Pharma Holding AB, 2022
- Anaphylaxis - Pipeline by Nasus Pharma Ltd, 2022
- Anaphylaxis - Pipeline by Orexo AB, 2022
- Anaphylaxis - Pipeline by Pharmacin BV, 2022
- Anaphylaxis - Pipeline by PureIMS BV, 2022
- Anaphylaxis - Dormant Projects, 2022
- Number of Products under Development for Anaphylaxis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allakos Inc
- Aquestive Therapeutics Inc
- ARS Pharmaceuticals Inc
- BioArdis LLC
- Bryn Pharma LLC
- Crossject SA
- Hoth Therapeutics Inc
- Klaria Pharma Holding AB
- Nasus Pharma Ltd
- Orexo AB
- Pharmacin BV
- PureIMS BV
